

Author Index

- Aduma, P.J., Gupta, S.V. and De Clercq, E., Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2'-deoxycytidine in combination with deaminase inhibitors, 111
- Alaghamandan, H.A., see Smee, D.F., 1
- Alaghamandan, H.A., see Smee, D.F., 91
- Alba, A.P.C., see De Fazio, G., 219
- Alteri, E., see Lazdins, J., 175
- Babu, J.R., see Schinazi, R.F., 265
- Bartlett, M.L., see Smee, D.F., 1
- Bernaerts, R., see Merta, A., 209
- Bernstein, D.I., see Reuman, P.D., 103
- Bernstein, D.I., see Stanberry, L.R., 227
- Brachwitz, H., see Matthes, E., 273
- Braitman, A., see Field, A.K., 43
- Bravo, F., see Stanberry, L.R., 227
- Burgin, C., see Lazdins, J., 175
- Burke, R.L., see Ho, R.J.Y., 187
- Cannon, D.L., see Schinazi, R.F., 265
- Černý, J., Votruba, I., Vonka, V., Rosenberg, I., Otmar, M. and Holý, A., Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase, 253
- Černý, J., see Holý, A., 295
- Ceruzzi, M., see Draper, K.G., 151
- Childs, F., see Stanberry, L.R., 227
- Chou, T.-C., see Soike, K.F., 165
- Chu, C.K., see Schinazi, R.F., 265
- Clark, J.M., see Field, A.K., 43
- Cload, P.A., see Mulder, J.W., 127
- Colacino, J.M., see Tang, J., 313
- Coutinho, R.A., see Mulder, J.W., 127
- Dalrymple, J.M., see Malinski, F.J., 139
- De Clercq, E., see Aduma, P.J., 111
- De Clercq, E., see De Fazio, G., 219
- De Clercq, E., see Holý, A., 295
- De Fazio, G., Alba, A.P.C., Vicente, M. and De Clercq, E., Antiviral activity of S-adenosylhomocysteine hydrolase inhibitors against plant viruses, 219
- De Wolf, F., see Mulder, J.W., 127
- Desideri, N., see Superti, F., 201
- Donelli, G., see Superti, F., 201
- Draper, K.G., Ceruzzi, M., Kmetz, M.E. and Sturzenbecker, L.J., Complementary oligonucleotide sequence inhibits both Vmw65 gene expression and replication of herpes simplex virus, 151
- Eghafona, N.O. and Emejuiwe, S.O., (Avid) rosette-forming cells as evidence for cellular immunity following measles virus vaccination in monkeys: correlation with the presence of haemagglutination inhibitory antibodies, 75
- Emejuiwe, S.O., see Eghafona, N.O., 75
- Eriksson, B.F.H., see Schinazi, R.F., 265
- Feng, J.S., see Li, S.B., 237
- Fiddian, A.P., see Mulder, J.W., 127
- Field, A.K., Tuomari, A.V., McGeever-Rubin, B., Terry, B.J., Mazina, K.E., Haffey, M.L., Hagen, M.E., Clark, J.M., Braitman, A., Slusarchyk, W.A., Young, M.G. and Zahler, R., (1 α ,2 β ,3 α)-9-[23-bis(hydroxymethyl)-cyclobutyl]guanine [(\pm)-BHCG or SQ 33054]: a potent and selective inhibitor of herpesviruses, 43
- Fong, C.K.Y., see Li, S.B., 237
- Fox, J.J., see Soike, K.F., 165
- Gangemi, J.D., see Lazdins, J., 175
- Gloff, C.A., see Soike, K.F., 165
- Goudsmit, J., see Mulder, J.W., 127
- Gupta, S.V., see Aduma, P.J., 111
- Haffey, M.L., see Field, A.K., 43
- Hagen, M.E., see Field, A.K., 43
- Harada, H., see Nagata, K., 11
- Harrison, C.J., see Stanberry, L.R., 227
- Hasegawa, A., see Ikeda, S., 327
- Hasty, S.E., see Malinski, F.J., 139
- Ho, R.J.Y., Burke, R.L. and Merigan, T.C., Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs, 187
- Holý, A., Votruba, I., Merta, A., Černý, J., Vesely, J., Vlach, J., Sedivá, K., Rosenberg, I., Otmar, M., Ĥrebabecky, H., Trávníček, M., Vonka, V., Snoeck, R. and De Clercq, E., Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro, 295
- Holý, A., see Černý, J., 253
- Holý, A., see Merta, A., 209

- Holý, A., see Votruba, I., 287
 Homma, J.Y., see Ikeda, S., 327
 Horisberger, M.A., Schrenk, R., Staiger, S., Leyvraz, A.R. and Martinod, S., Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid, 53
 Ĥrebabecky, H., see Holý, A., 295
 Ĥrebabecky, H., see Merta, A., 209
 Ĥrebabecky, H., see Votruba, I., 287
 Hsiung, G.D., see Li, S.B., 237
- Ikeda, S., Nishimura, C., Matsuura, M., Homma, J.Y., Kiso, M. and Hasegawa, A., Effect of acyl substituents of synthetic lipid A-subunit analogues on their immunomodulating antiviral activity (Short Communication), 327
 Ishihama, A., see Nagata, K., 11
 Ishitsuka, H., see Ninomiya, Y., 61
- Jin, A., see Smee, D.F., 91
 Jolley, W.B., see Smee, D.F., 91
 Jones, M.M., see Smee, D.F., 1
- Keely, S.P., see Reuman, P.D., 103
 Kiso, M., see Ikeda, S., 327
 Kmetz, M.E., see Draper, K.G., 151
 Konno, K., see Nagata, K., 11
 Kovacs, T., see Subramanian, M., 81
- Lange, J.M.A., see Mulder, J.W., 127
 Langen, P., see Matthes, E., 273
 Larsen, S.H., see Tang, J., 313
 Lazdins, J., Alteri, E., Woods Cook, K., Burgin, C. and Gangemi, J.D., Use of human monocytes in the evaluation of antiviral drugs: quantitation of HSV-1 cytopathic effects, 175
 Lenard, J., see Subramanian, M., 81
 Lesiak, K., see Subramanian, M., 81
 Leyvraz, A.R., see Horisberger, M.A., 53
 Li, S.B., Yang, Z.H., Feng, J.S., Fong, C.K.Y., Lucia, H.L. and Hsiung, G.D., Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs, 237
 Lucia, H.L., see Li, S.B., 237
- Maidhof, A., see Matthes, E., 273
 Malinski, F.J., Hasty, S.E., Ussery, M.A. and Dalrymple, J.M., Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys, 139
 Martinod, S., see Horisberger, M.A., 53
 Marziano, M.L., see Superti, F., 201
- Matsuura, M., see Ikeda, S., 327
 Matthes, E., Langen, P., Brachwitz, H., Schröder, H.C., Maidhof, A., Weiler, B.E., Renneisen, K. and Müller, W.E.G., Alteration of DNA topoisomerase II activity during infection of H9 cells by human immunodeficiency virus type 1 in vitro: a target for potential therapeutic agents, 273
 Mazina, K.E., see Field, A.K., 43
 McGeever-Rubin, B., see Field, A.K., 43
 Merigan, T.C., see Ho, R.J.Y., 187
 Merta, A., Votruba, I., Rosenberg, I., Otmar, M., Ĥrebabecky, H., Bernaerts, R. and Holý, A., Inhibition of herpes simplex virus DNA polymerase by diphosphates of acrylic phosphonylmethoxyalkyl nucleotide analogues, 209
 Merta, A., see Holý, A., 295
 Merta, A., see Votruba, I., 287
 Mulder, J.W., De Wolf, F., Goudsmit, J., Cload, P.A., Coutinho, R.A., Fiddian, A.P., Schellekens, P.T., Van der Noordaa, J. and Lange, J.M.A., Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects, 127
 Müller, W.E.G., see Matthes, E., 273
- Nagata, K., Sakagami, H., Harada, H., Nonoyama, M., Ishihama, A. and Konno, K., Inhibition of influenza virus infection by pine cone antitumor substances, 11
 Nasr, M., see Schinazi, R.F., 265
 Ninomiya, Y., Shimma, N. and Ishitsuka, H., Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides, 61
 Nishimura, C., see Ikeda, S., 327
 Nonoyama, M., see Nagata, K., 11
- Orsi, N., see Superti, F., 201
 Oswald, B.J., see Schinazi, R.F., 265
 Otmar, M., see Černý, J., 253
 Otmar, M., see Holý, A., 295
 Otmar, M., see Merta, A., 209
 Otmar, M., see Votruba, I., 287
- Reece, A.L., see Stanberry, L.R., 227
 Renneisen, K., see Matthes, E., 273
 Reuman, P.D., Bernstein, D.I., Keely, S.P., Sherwood, J.R., Young, E.C. and Schiff, G.M., Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition, 103
 Revankar, G.R., see Smee, D.F., 1
 Robins, R.K., see Smee, D.F., 1
 Rosenberg, I., see Černý, J., 253

- Rosenberg, I., see Holý, A., 295
 Rosenberg, I., see Merta, A., 209
 Rosenberg, I., see Votruba, I., 287
- Saalmann, V., see Schinazi, R.F., 265
 Sakagami, H., see Nagata, K., 11
 Schellekens, P.T., see Mulder, J.W., 127
 Schiff, G.M., see Reuman, P.D., 103
 Schinazi, R.F., Chu, C.K., Babu, J.R., Oswald, B.J., Saalmann, V., Cannon, D.L., Eriksson, B.F.H. and Nasr, M., Anthraquinones as a new class of antiviral agents against human immunodeficiency virus (Short Communication), 265
 Schrenk, R., see Horisberger, M.A., 53
 Schröder, H.C., see Matthes, E., 273
 Sedivá, K., see Holý, A., 295
 Seganti, L., see Superti, F., 201
 Sharma, B.S., see Smee, D.F., 91
 Sherwood, J.R., see Reuman, P.D., 103
 Shimma, N., see Ninomiya, Y., 61
 Slusarchyk, W.A., see Field, A.K., 43
 Smee, D.F., Alaghamandan, H.A., Jin, A., Sharma, B.S. and Jolley, W.B., Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice, 91
 Smee, D.F., Bartlett, M.L., Alaghamandan, H.A., Jones, M.M., Revankar, G.R. and Robins, R.K., 4,6-Dibenzamidopyrazolo[3,4-d]pyrimidine is a highly selective inhibitor of cytomegalovirus adsorption to cells, 1
 Snoeck, R., see Holý, A., 295
 Soike, K.F., Chou, T.-C., Fox, J.J., Watanabe, K.A. and Gloff, C.A., Inhibition of Simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1- β -D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon- β , 165
 Spitzer, W., see Tang, J., 313
 Staiger, S., see Horisberger, M.A., 53
 Stanberry, L.R., Harrison, C.J., Bravo, F., Childs, F., Reece, A.L. and Bernstein, D.I., Recurrent genital herpes in the guinea pig augmented by ultraviolet irradiation: effects of treatment with acyclovir, 227
 Stein, M.L., see Superti, F., 201
 Sturzenbecker, L.J., see Draper, K.G., 151
 Subramanian, M., Kovacs, T., Lesiak, K., Torrence, P.F. and Lenard, J., Inhibition of the RNA polymerase of vesicular stomatitis virus ppp5'A2'p5'A and related compounds, 81
 Superti, F., Seganti, L., Orsi, N., Desideri, N., Stein, M.L., Tinari, A., Marziano, M.L. and Donelli, G., In vitro effect of synthetic flavanoids on astrovirus infection (Short Communication), 201
 Sühnel, J., Evaluation of synergism or antagonism for the combined action of antiviral agents, 23
 Tang, J., Colacino, J.M., Larsen, S.H. and Spitzer, W., Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses, 313
 Terry, B.J., see Field, A.K., 43
 Tinari, A., see Superti, F., 201
 Torrence, P.F., see Subramanian, M., 81
 Trávníček, M., see Holý, A., 295
 Trávníček, M., see Votruba, I., 287
 Tuomari, A.V., see Field, A.K., 43
 Ussery, M.A., see Malinski, F.J., 139
 Van der Noordaa, J., see Mulder, J.W., 127
 Vesely, J., see Holý, A., 295
 Vicente, M., see De Fazio, G., 219
 Vlach, J., see Holý, A., 295
 Vonka, V., see Černý, J., 253
 Vonka, V., see Holý, A., 295
 Votruba, I., Trávníček, M., Rosenberg, I., Otmar, M., Merta, A., Hřebabecky, H. and Holý, A., Inhibition of avian myeloblastosis virus reverse transcriptase by diphosphates of acyclic phosphonylmethyl nucleotide analogues, 287
 Votruba, I., see Černý, J., 253
 Votruba, I., see Holý, A., 295
 Votruba, I., see Merta, A., 209
 Watanabe, K.A., see Soike, K.F., 165
 Weiler, B.E., see Matthes, E., 273
 Woods Cook, K., see Lazdins, J., 175
 Yang, Z.H., see Li, S.B., 237
 Young, E.C., see Reuman, P.D., 103
 Young, M.G., see Field, A.K., 43
 Zahler, R., see Field, A.K., 43

Subject Index

- Acyclic nucleotide analogue**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, HMPA, HPMP, PMEA, 295
- Acyclovir**, Recurrent genital herpes, Herpes simplex virus, Guinea pig model, 227
- (RS)-AHPA**, SAH hydrolase inhibitor, (RS)-DHPA, C-c3Ado, Plant virus, TMV, PVX, 219
- Antagonism, Synergism**, Antiviral combination experiment, Isobole method, Mathematical modeling, 23
- Anthraquinone**, Anti-HIV-1 activity, Reverse transcriptase, Hypericin, 265
- Anti-HIV-1 activity**, Anthraquinone, Reverse transcriptase, Hypericin, 265
- Antigen presentation**, Immunotherapy, HSV, Liposome, Recurrence, 187
- Antitherpes activity**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), dNTP pool, HSV-infected cell, 111
- Antirhinovirus agent**, Ro 09-0410, Chalcone amide, Binding site, Drug resistant HRV-2 subline, 61
- Antiviral combination experiment**, Synergism, Antagonism, Isobole method, Mathematical modeling, 23
- Antiviral agent**, Cytomegalovirus infection, Nucleoside analog, HPMP, Cultured cell, Guinea pig, 237
- 2-5 As**, Dinucleotide, Vesicular stomatitis virus, RNA polymerase, Inhibition of RNA synthesis, 81
- Astrovirus**, Synthetic flavanoid, 201
- Asymptomatic HIV infection**, HIV-1 p24 antigenemia, Zidovudine treatment, 127
- Avian myeloblastosis virus**, Reverse transcriptase, Retrovirus, PMEA, 287
- (-)BHCg**, HSV-1, HSV-2, 43
- Binding site**, Antirhinovirus agent, Ro 09-0410, Chalcone amide, Drug resistant HRV-2 subline, 61
- C-c3Ado**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, Plant virus, TMV, PVX, 219
- Cat Mx protein**, Interferon, Feline viral disease, 53
- Cell-mediated immunity**, Measles virus, 75
- Chalcone amide**, Antirhinovirus agent, Ro 09-0410, Binding site, Drug resistant HRV-2 subline, 61
- CMV receptor**, Human CMV, Mouse CMV, Monkey CMV, 1
- Cultured cell**, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMP, Guinea pig, 237
- Cytomegalovirus infection**, Antiviral agent, Nucleoside analog, HPMP, Cultured cell, Guinea pig, 237
- (RS)-DHPA**, SAH hydrolase inhibitor, (RS)-AHPA, C-c3Ado, Plant virus, TMV, PVX, 219
- Dengue**, Ribavirin, Rhesus monkey, 139
- Differentiation**, Human monocyte, Herpes simplex virus type 1, Interferon-, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Dinucleotide**, 2-5 As, Vesicular stomatitis virus, RNA polymerase, Inhibition of RNA synthesis, 81
- DNA polymerase inhibition**, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, HMPA, PMEA, 209
- DNA topoisomerase II activity**, Hg cells, HIV-1, 273
- Drug resistant HRV-2 subline**, Antirhinovirus agent, Ro 09-0410, Chalcone amide, Binding site, 61
- Drug screening**, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon- α , Poly I:C-LC, acyclovir, Viability index, 175
- (E)-5-(2-bromovinyl)-2'-deoxycytidine**, Tetrahydrodeoxyuridine (deaminase inhibitor), Antitherpes activity, dNTP pool, HSV-infected cell, 111
- Enveloped virus**, Hypericin, Pseudophycerycin, Virucidal agent, Non-enveloped virus, 313
- FEAU**, Hu rIFN, Simian varicella virus, Monkey, 165
- Feline viral disease**, Interferon, Cat Mx protein, 53
- Guanosine analog**, Nucleoside analog, Immune modulator, 91
- Guinea pig model**, Acyclovir, Recurrent genital herpes, Herpes simplex virus, 227
- Guinea pig**, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMP, Cultured cell, 237

- Herpes simplex virus**, Oligonucleotide inhibition, 151
- Herpes simplex virus type 1**, Human monocyte, Differentiation, Interferon- α , Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Herpes simplex virus**, DNA polymerase inhibition, Phosphonylmethoxyalkylpurine,-pyrimidine, HPMPA, PMEA, 209
- Herpes simplex virus**, Acyclovir, Recurrent genital herpes, Guinea pig model, 227
- Hg cells**, HIV-1, DNA topoisomerase II activity, 273
- HIV-1 p24 antigenemia**, Asymptomatic HIV infection, Zidovudine treatment, 127
- HIV-1**, Hg cells, DNA topoisomerase II activity, 273
- HPMPA**, DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, PMEA, 209
- HPMPA**, HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, PMEA, 253
- HPMPA**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, PMEA, 295
- HPMPC**, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, Cultured cell, Guinea pig, 237
- HPMPC**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, PMEA, 295
- HSV**, Immunotherapy, Liposome, Recurrence, Antigen presentation, 187
- HSV-1 encoded ribonucleotide reductase**, Phosphonylmethyl derivative of acyclic nucleoside analog, HPMPA, PMEA, 253
- HSV-1**, (-)BHCG, HSV-2, 43
- HSV-2**, (-)BHCG, HSV-1, 43
- HSV-infected cell**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, dNTP pool, 111
- Hu rIFN**, FEAU, Simian varicella virus, Monkey, 165
- Human CMV**, Mouse CMV, Monkey CMV, CMV receptor, 1
- Human monocyte**, Differentiation, Herpes simplex virus type 1, Interferon- α , Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Hypericin**, Anthraquinone, Anti-HIV-1 activity, Reverse transcriptase, 265
- Hypericin**, Pseudohypericin, Virucidal agent, Enveloped virus, Non-enveloped virus, 313
- Immune modulator**, Nucleoside analog, Guanosine analog, 91
- Immunomodulator**, Lipid A analogue, Interferon, Natural killer (NK) cell, 327
- Immunotherapy**, HSV, Liposome, Recurrence, Antigen presentation, 187
- Influenza virus**, Pine cone extract, RNA dependent RNA polymerase, Influenza, Nasal IgA, 103
- Inhibition of RNA synthesis**, 2-5 As, Dinucleotide, Vesicular stomatitis virus, RNA polymerase, 81
- Interferon**, Cat Mx protein, Feline viral disease, 53
- Interferon- α** , Human monocyte, Differentiation, Herpes simplex virus type 1, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
- Interferon**, Immunomodulator, Lipid A analogue, Natural killer (NK) cell, 327
- Isobole method**, Synergism, Antagonism, Antiviral combination experiment, Mathematical modeling, 23
- Lipid A analogue**, Immunomodulator, Interferon, Natural killer (NK) cell, 327
- Liposome**, Immunotherapy, HSV, Recurrence, Antigen presentation, 187
- Mathematical modeling**, Synergism, Antagonism, Antiviral combination experiment, Isobole method, 23
- Measles virus**, Cell-mediated immunity, 75
- Monkey CMV**, Human CMV, Mouse CMV, CMV receptor, 1
- Monkey**, FEAU, Hu rIFN, Simian varicella virus, 165
- Mouse CMV**, Human CMV, Monkey CMV, CMV receptor, 1
- N-(2-phosphonylmethoxyethyl) derivative**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, Acyclic nucleotide analogue, HPMPA, HPMPC, PMEA, 295
- N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives**, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, HPMPC, PMEA, 295
- Nasal IgA**, Influenza, 103
- Natural killer (NK) cell**, Immunomodulator, Lipid A analogue, Interferon, 327
- Non-enveloped virus**, Hypericin, Pseudohypericin, Virucidal agent, Enveloped virus, 313
- dNTP pool**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, HSV-infected cell, 111

- Nucleoside analog**, Immune modulator, Guanosine analog, 91
- Nucleoside analog**, Cytomegalovirus infection, Antiviral agent, HPMPC, Cultured cell, Guinea pig, 237
- Oligonucleotide inhibition**, Herpes simplex virus, 151
- Phosphonylmethyl derivative of acyclic nucleoside analog**, HSV-1 encoded ribonucleotide reductase, HPMPA, PMEA, 253
- Pine cone extract**, Influenza virus, RNA dependent RNA polymerase, 11
- Plant virus**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, TMV, PVX, 219
- PMEA**, DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, HPMPA, 209
- PMEA**, HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, HPMPA, 253
- PMEA**, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivatives, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, HPMPC, 295
- PMEA**, Reverse transcriptase, Retrovirus, Avian myeloblastosis virus, 287
- Phosphonylmethoxyalkylpurine,-pyrimidine**, DNA polymerase inhibition, Herpes simplex virus, HPMPA, PMEA, 209
- Poly I:C-LC, acyclovir**, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon- α , Viability index, Drug screening, 175
- Pseudophypericin**, Hypericin, Virucidal agent, Enveloped virus, Non-enveloped virus, 313
- PVX**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, TMV, 219
- RNA dependent RNA polymerase**, Influenza virus, Pine cone extract, 11
- RNA polymerase**, 2-5 As, Dinucleotide, Vesicular stomatitis virus, Inhibition of RNA synthesis, 81
- Recurrence**, Immunotherapy, HSV, Liposome, Antigen presentation, 187
- Recurrent genital herpes**, Acyclovir, Herpes simplex virus, Guinea pig model, 227
- Retrovirus**, Reverse transcriptase, PMEA, Avian myeloblastosis virus, 287
- Reverse transcriptase**, Anthraquinone, Anti-HIV-1 activity, Hypericin, 265
- Reverse transcriptase**, Retrovirus, PMEA, Avian myeloblastosis virus, 287
- Rhesus monkey**, Ribavirin, Dengue, 139
- Ribavirin**, Dengue, Rhesus monkey, 139
- Ro 09-0410**, Antirhinovirus agent, Chalcone amide, Binding site, Drug resistant HRV-2 subline, 61
- SAH hydrolase inhibitor**, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, TMV, PVX, 219
- Simian varicella virus**, FEAU, Hu rIFN, Monkey, 165
- Synergism**, Antagonism, Antiviral combination experiment, Isobole method, Mathematical modeling, 23
- Synthetic flavanoid**, Astrovirus, 201
- Tetrahydrodeoxyuridine (deaminase inhibitor)**, (E)-5-(2-bromovinyl)-2'-deoxycytidine, Anti-herpes activity, dNTP pool, HSV-infected cell, 111
- TMV**, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, PVX, 219
- Vesicular stomatitis virus**, 2-5 As, Dinucleotide, RNA polymerase, Inhibition of RNA synthesis, 81
- Viability index**, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon-, Poly I:C-LC, acyclovir, Drug screening, 175
- Virucidal agent**, Hypericin, Pseudophypericin, Enveloped virus, Non-enveloped virus, 313
- Zidovudine treatment**, Asymptomatic HIV infection, HIV-1 p24 antigenemia, 127